Pasithea Therapeutics Corp.
KTTANASDAQHealthcare● Active
$0.58
$-0.01(-1.61%)
Market Cap$4283703
P/E Ratio—
52W High$2.06
52W Low$0.281
Pasithea Therapeutics Corp. (KTTA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KTTA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.12
Est. -$0.45 · +73.3%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
KTTA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.16 | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | Jun 3, 2026 | -$3.40 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.45 | -$0.12 | +73.3% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 30, 2026 | -$0.18 | -$0.89 | -394.4% | — | $0.00B | — |
| — Q1 FY2026 | Feb 25, 2026 | -$0.18 | -$0.18 | +0.0% | — | $0.00B | — |
| — Q4 FY2025 | Nov 13, 2025 | — | -$0.41 | — | — | — | — |
| — Q3 FY2025 | Aug 14, 2025 | — | -$0.66 | — | — | — | — |
| — Q2 FY2025 | May 15, 2025 | — | -$1.61 | — | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.16
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 3, 2026
EPS Actual
—
EPS Est.
-$3.40
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.12
EPS Est.
-$0.45
EPS Surpr.
+73.3%
Revenue
—
Q1 FY2026
Mar 30, 2026Miss
EPS Actual
-$0.89
EPS Est.
-$0.18
EPS Surpr.
-394.4%
Revenue
—
Q1 FY2026
Feb 25, 2026
EPS Actual
-$0.18
EPS Est.
-$0.18
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2025
Nov 13, 2025
EPS Actual
-$0.41
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 14, 2025
EPS Actual
-$0.66
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 15, 2025
EPS Actual
-$1.61
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $-3.80 | $-3.80 | $-3.80 | 1 |
| Q4 FY2027 | $-3.60 | $-3.60 | $-3.60 | 1 |
| Q3 FY2027 | $-3.40 | $-3.40 | $-3.40 | 1 |
| Q2 FY2027 | $-3.40 | $-3.40 | $-3.40 | 1 |
| Q1 FY2027 | $-3.40 | $-3.40 | $-3.40 | 1 |
| Q4 FY2026 | $-0.24 | $-0.24 | $-0.24 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +73.3% | $0.79 | $0.78 | -1.78% |
| ▼ Q1 FY2026 | Mar 30, 2026 | -394.4% | $0.74 | $0.72 | -3.38% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +0.0% | $0.87 | $0.85 | -1.78% |
| — Q4 FY2025 | Nov 13, 2025 | — | $0.70 | $0.70 | +0.01% |
| — Q3 FY2025 | Aug 14, 2025 | — | $0.72 | $0.70 | -2.13% |
| — Q2 FY2025 | May 15, 2025 | — | $0.96 | $0.86 | -9.90% |
| — Q1 FY2025 | Mar 24, 2025 | — | $1.24 | $1.25 | +0.81% |
| — Q4 FY2024 | Nov 13, 2024 | — | $3.36 | $3.42 | +1.79% |
Q2 FY2026-1.78%
Report Date
May 15, 2026
EPS Beat/Miss
+73.3%
Price Before
$0.79
Price After
$0.78
Q1 FY2026-3.38%
Report Date
Mar 30, 2026
EPS Beat/Miss
-394.4%
Price Before
$0.74
Price After
$0.72
Q1 FY2026-1.78%
Report Date
Feb 25, 2026
EPS Beat/Miss
+0.0%
Price Before
$0.87
Price After
$0.85
Q4 FY2025+0.01%
Report Date
Nov 13, 2025
EPS Beat/Miss
—
Price Before
$0.70
Price After
$0.70
Q3 FY2025-2.13%
Report Date
Aug 14, 2025
EPS Beat/Miss
—
Price Before
$0.72
Price After
$0.70
Q2 FY2025-9.90%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$0.96
Price After
$0.86
Q1 FY2025+0.81%
Report Date
Mar 24, 2025
EPS Beat/Miss
—
Price Before
$1.24
Price After
$1.25
Q4 FY2024+1.79%
Report Date
Nov 13, 2024
EPS Beat/Miss
—
Price Before
$3.36
Price After
$3.42
Avg Beat Reaction-1.78%
Avg Miss Reaction-3.38%
Beat Rate2 / 8 quarters
Largest Move-9.90% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KTTA ends December
Pasithea Therapeutics Corp. (KTTA) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.12 — beating the analyst consensus of $-0.45 by +73.3%. The next KTTA earnings date is expected around September 1, 2026.
Each quarter, investors track KTTA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KTTA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KTTA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KTTA earnings · 5 questionsPasithea Therapeutics Corp.'s next earnings report is expected around September 1, 2026. KTTA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KTTA historically reports after market close (AMC).
KTTA earnings datewhen is KTTA earningsKTTA next earnings datewhen does KTTA report earningsKTTA earnings calendar
▸ Source: FMP · Pasithea Therapeutics Corp. SEC filings · US GAAP · Pasithea Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026